Hydroxyurea in children: present and future.
Children with sickle cell anemia provide the best opportunity to assess the efficacy of hydroxyurea (HU) in preventing complications and progressive organ damage. The possibility of treating infants with sickle cell disease (SCD) to inhibit the development of organ dysfunction may be the most important future use of HU. The possibility even exists that instituting HU in the neonate may stop the fetal-to-adult globin chain switch and thus markedly change the clinical phenotype of SCD. Recent data suggest HU may also be especially beneficial in children not only by increasing hemoglobin F (HbF), but also by altering the adhesive receptors expressed on red blood cells and vascular endothelium, further increasing the possibility that vasculopathy can be prevented. Six pediatric trials that included small numbers of severely ill patients have been reported recently. All patients received relatively standard HU doses. All studies reported a significant improvement in HbF and mean corpuscular volume and a mild to marked increase in hemoglobin. The clinical response to HU in children with SCD seems to be consistent. The National Institutes of Health pediatric multicenter trial should help answer the question of short-term HU toxicity; however, questions remain concerning long-term risks, such as carcinogenesis, gametogenesis, marrow toxicity, growth retardation, and chromosomal damage. Long-term studies are needed to answer these questions. The future treatment of most children with SCD with HU alone or in combination with other agents looks promising, and long-term trials are warranted.
Vichinsky
E P
EP
Department of Hematology/Oncology and the Sickle Cell Center, Children's Hospital Oakland, CA 94609, USA.
D000755:Anemia, Sickle Cell / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000986:Antisickling Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D005319:Fetal Hemoglobin / Q000378:metabolism; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000986:Antisickling Agents; D005319:Fetal Hemoglobin; D006918:Hydroxyurea